



Press Release

Half-Year MEDIAN Technologies liquidity contract statement contracted with AUREL BGC Company

Sophia Antipolis, France – July 6th 2016 – Under the liquidity contract entrusted by MEDIAN Technologies to AUREL BGC, the following resources were listed in the liquidity account as at June 30, 2016:

- € 72,165.89
- 18,833 shares

For information, as at December 31, 2015, the following resources were listed in the liquidity account:

- € 90,602.01
- 17,303 shares



About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care.

MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechologies.com

"We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients."



Contacts

MEDIAN Technologies

Fredrik Brag, CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Press

ALIZE RP
Caroline Carmagnol
Wendy Rigal
+ 33 1 44 54 36 66
median@alizerp.com

Investors

ACTIFIN
Ghislaine Gasparetto
+ 33 1 56 88 11 11
ggasparetto@actifin.fr